Market Access Views & Analysis

Views & Analysis

Market Access

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

Market Access

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

Market Access

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

Market Access

At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.

Market Access

A comparison of the US MFN and German MFG.

Market Access

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.